Early AFP placement is associated with lower mortality,31 particularly when initiated before revascularization.21, 34, 35 This knowledge was based on registry data in the absence of randomized trials during most of the HaCRA implementation.31, 34, 36 Nowadays, data from clinical trials support the initial use of an AFP in selected cases of AMI-CS,5, 37 as the DanGer-Shock trial was very selective in order to collect high-risk shock in large anterior AMI but to evade excess anoxic brain damage biasing the mortality outcome in resuscitated patients.38 The gene discussed is AFP; the disease is brain injury.